Pa. Panel Urged To Revive Risperdal Breast-Growth Case
A Philadelphia judge's mid-trial decision axing claims against a Johnson & Johnson unit over breast growth allegedly linked to the antipsychotic medication Risperdal came under fire Wednesday as a state appeals...To view the full article, register now.
Already a subscriber? Click here to view full article